[1]
Perez-Matos M, Morales-Alvarez M, Mendivil C. Lipids: A suitable therapeutic target in diabetic neuropathy? J Diabetes Res 2017; 2017: 6943851.
[2]
Nukada H. Ischemia and diabetic neuropathy. Diabetes and the
Nervous System. 3rd ed. Elsevier Science . 2014; 126: pp. 469-87.
[3]
Allen M, Doherty T, Rice C, Kimpinski K. Physiology in Medicine: neuromuscular consequences of diabetic neuropathy. J Appl Physiol 2016; 121(1): 1-6.
[4]
Sun M, Zhang M, Shen J, Yan J, Zhou B. Critical appraisal of international guidelines for the management of diabetic neuropathy: is there global agreement in the internet era? Int J Endocrinol 2015; 1-11.
[5]
Sung J-Y, Tani J, Chang T-S, Lin CS-Y. Uncovering sensory ax-onal dysfunction in asymptomatic type 2 diabetic neuropathy. PLoS One 2017; 12(2): e0171223.
[6]
Greig M, Tesfaye S, Selvarajah D, Wilkinson I. Insights into the pathogenesis and treatment of painful diabetic neuropathy. Diabetes
and the nervous system. 3rd ed. Elsevier Science. 2014; 126: pp. (3)559-78.
[7]
Peltier A, Goutman SA, Callaghan BC. Painful diabetic neuropa-thy. BMJ 2014; 348: g1799.
[8]
Papanas N, Ziegler D. Risk factors and comorbidities in diabetic neuropathy: an update 2015. Rev Diabet Stud 2015; 12(1-2): 48-62.
[9]
Shakeel M. Recent advances in understanding the role of oxidative stress in diabetic neuropathy. Diabetes Metab Syndr 2015; 9(4): 373-8.
[10]
Sandireddy R, Yerra V, Areti A, Komirishetty P, Kumar A. Neuroinflammation and oxidative stress in diabetic neuropathy: futuristic strategies based on these targets. Int J Endocrinol 2014; 1-10.
[11]
Chilelli N, Burlina S, Lapolla A. AGEs, rather than hyperglycemia, are responsible for microvascular complications in diabetes: A “glycoxidation-centric” point of view. Nutr Metab Cardiovasc Dis 2013; 23(10): 913-9.
[12]
Tesfaye S, Selvarajah D. Advances in the epidemiology, pathogenesis and management of diabetic peripheral neuropathy. Diabetes Metab Res Rev 2012; 28: 8-14.
[13]
Abbott C, Malik R, van Ross E, Kulkarni J, Boulton A. Prevalence and characteristics of painful diabetic neuropathy in a large community-based diabetic population in the U.K. Diabetes Care 2011; 34(10): 2220-4.
[14]
Assaad-Khalil S, Zaki A, Rehim A, et al. Prevalence of diabetic foot disorders and related risk factors among Egyptian subjects with diabetes. Prim Care Diabetes 2015; 9(4): 297-303.
[15]
Geelen C, Smeets R, Schmitz S, van den Bergh J, Goossens M, Verbunt J. Anxiety affects disability and quality of life in patients with painful diabetic neuropathy. Eur J Pain 2017; 21(10): 1632-41.
[16]
Ang L, Jaiswal M, Martin C, Pop-Busui R. Glucose control and diabetic neuropathy: lessons from recent large clinical trials. Curr Diab Rep 2014; 14(9): 528.
[17]
Tesfaye S, Boulton A, Dyck P, et al. Diabetic neuropathies: up-date on definitions, diagnostic criteria, estimation of severity, and treatments. Diabetes Care 2010; 33(10): 2285-93.
[18]
BOULTON A. Diabetic neuropathy and foot complications. Diabetes
and the Nervous System. 3rd ed. Elsevier Science 2014; 126: 97-107.
[19]
Todorovic SM. Treating painful diabetic neuropathy: Preventing pain vs. blocking pain by targeting nociceptive ion channels in sensory neurons. Int Rev Neurobiol 2016; 127: 211-25.
[20]
Raputova J, Srotova I, Vlckova E, et al. Sensory phenotype and risk factors for painful diabetic neuropathy. Pain 2017; 158(12): 2340-53.
[21]
Goel A, Shivaprasad C, Kolly A, Sarathi HAV, Atluri S. Comparison of electrochemical skin conductance and vibration perception threshold measurement in the detection of early diabetic neuropathy. PLoS One 2017; 12(9): e0183973.
[22]
Bril V, England J, Franklin GM, et al. Evidence-based guideline: Treatment of painful diabetic neuropathy. Am Acad Neurol 2011; 76: 1758-65.
[23]
Garcia-Alcala H, Santos VC, Islas MS, et al. Treatment withα-Lipoic acid over 16 weeks in type 2 diabetic patients with symptomatic polyneuropathy who responded to initial 4-week high-dose loading. J Diabetes Res 2015; 2015: 1-8.
[24]
Ziegler D, Schneider E, Boess F, Berggren L, Birklein F. Impact of comorbidities on pharmacotherapy of painful diabetic neuropathy in clinical practice. J Diabetes Complications 2014; 28(5): 698-704.
[25]
Dy SM, Bennett WL, Sharma R, et al. AHRQ comparative effectiveness
reviews In: Preventing complications and treating symptoms of diabetic peripheral neuropathy Rockville. Agency for Healthcare Research and Quality (US) 2017.
[26]
Finnerup N, Attal N, Haroutounian S. Pharmacotherapy for neuro-pathic pain in adults: a systematic review and meta-analysis. J Vasc Surg 2015; 62(4): 1091.
[27]
Yasuda H. Pharmacological interventions for painful diabetic neuropathy: Comparative analysis using network meta-analysis. J Diabetes Investig 2015; 6(6): 620-2.
[28]
Oyenihi A, Ayeleso A, Mukwevho E, Masola B. Antioxidant strategies in the management of diabetic neuropathy. BioMed Res Int 2015; 2015: 1-15.
[29]
Calabek B, Callaghan B, Feldman E. Therapy for diabetic neuropa-thy: an overview Diabetes and the Nervous System. 3rd ed. Elsevier
Science . 2014; 126: 317-3.
[30]
Van Dam P. Oxidative stress and diabetic neuropathy: pathophysi-ological mechanisms and treatment perspectives. J Peripher Nerv Syst 2002; 7(4): 246-8.
[31]
Papanas N, Ziegler D. Efficacy of α- lipoic acid in diabetic neuropathy. Expert Opin Pharmacother 2014; 15(18): 2721-31.
[32]
Vallianou N, Evangelopoulos A, Koutalas P. Alpha-lipoic acid and diabetic neuropathy. Rev Diabet Stud 2009; 6(4): 230-6.
44
4
1
1